FINWIRES · TerminalLIVE
FINWIRES

HKG:6628

2 stories mentioning HKG:6628Updated 43d ago

Every FINWIRES story that references HKG:6628, newest first.

Asia

Transcenta Secures 7 Million Yuan Milestone Payment Under EirGenix Bio-Platform Deal; Shares Fall 7%

Transcenta (HKG:6628) received a 7 million yuan milestone payment tied to the out-licensing of its highly intensified continuous bioprocessing platform, according to a Tuesday Hong Kong bourse filing.Shares of the biopharmaceutical company were down over 7% in late morning trade on Wednesday.The payment followed progress under the company's collaboration and non-exclusive licensing agreement with EirGenix (TPE:6589).

HKG:6628TPE:6589
Asia

Transcenta Says Ozekibart Found to Benefit Patients With Colorectal Cancer

Transcenta (HKG:6628) said updated data from the phase 1/2 study of ozekibart found the drug benefited patients with colorectal cancer and kept the disease at bay, according to a Thursday filing with the Hong Kong bourse.The firm holds a license to develop and commercialize the drug in the greater China region.Results published by the company's partner Inhibrx Biosciences showed the medicine had an objective response rate of 20% in patients who had been treated with other drugs previously.The median progression-free survival among the 45 evaluable patients from the trial was 5.5 months, while the overall disease control rate stood at 87%.Inhibrx plans to meet with the U.S. Food and Drug Administration in the second half of 2026 to discuss further trials of ozekibart in colorectal cancer.Meanwhile, Inhibrx submitted a biologics license application with the U.S. Food and Drug Administration seeking approval for ozekibart in conventional chondrosarcoma, a type of bone cancer.

HKG:6628

Track with the FINWIRES app suite

FolioX
FolioX
Track HKG:6628 in your portfolio
WheelAI
WheelAI
Analyze HKG:6628 options with the wheel strategy
StockInsider
StockInsider
See market sentiment on HKG:6628